Reported 5,872 shares, down 1,813,232 (99.7%) from the prior quarter.
Reported value -99.6%; share count -99.7% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2022-03-31 | 8965000 |
| 2022-06-30 | 7386000 |
| 2022-09-30 | 5843000 |
| 2022-12-31 | 14499429 |
| 2023-03-31 | 13392464 |
| 2023-06-30 | 18336569 |
| 2023-09-30 | 68585 |
| 2023-12-31 | 65729 |
| 2024-03-31 | 4743685 |
| 2024-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2024 | Reduced | 0 | -450,065 (-100.0%) | 0 | $0 | 2024-08-13 | |
| Q1 2024 | Added | 450,065 | +444,212 (7589.5%) | 0.02% | $4,743,685 | 2024-05-13 | |
| Q4 2023 | Reduced | 5,853 | -19 (-0.3%) | < 0.01% | $65,729 | 2024-02-13 | |
| Q3 2023 | Reduced | 5,872 | -1,813,232 (-99.7%) | < 0.01% | $68,585 | 2023-11-13 | |
| Q2 2023 | Added | 1,819,104 | +4,407 (0.2%) | 0.11% | $18,336,569 | 2023-08-04 | |
| Q1 2023 | Unchanged | 1,814,697 | 0 (0.0%) | 0.09% | $13,392,464 | 2023-05-12 | |
| Q4 2022 | Unchanged | 1,814,697 | 0 (0.0%) | 0.1% | $14,499,429 | 2023-02-10 | |
| Q3 2022 | Unchanged | 1,814,697 | 0 (0.0%) | 0.04% | $5,843,000 | 2022-11-14 | |
| Q2 2022 | Unchanged | 1,814,697 | 0 (0.0%) | 0.05% | $7,386,000 | 2022-08-12 | |
| Q1 2022 | New | 1,814,697 | +1,814,697 (0.0%) | 0.05% | $8,965,000 | 2022-05-13 |
Who else reported the position
234 managers reported ROIVANT SCIENCES LTD for Q3 2023.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| QVT Financial LP | Reduced | 112,541,536 | -10,000,000 | 74.33% | $1,314,485,140 | 8 qtrs |
| VIKING GLOBAL INVESTORS LP | Reduced | 73,434,301 | -1,804,399 | 3.48% | $857,712,636 | 8 qtrs |
| SB INVESTMENT ADVISERS UK LTD | Reduced | 73,031,667 | -10,000,000 | 7.03% | $853,009,871 | 8 qtrs |
| FMR LLC | Added | 38,910,625 | +2,913,491 | 0.04% | $454,476,104 | 8 qtrs |
| MORGAN STANLEY | Added | 19,311,631 | +6,324,915 | 0.02% | $225,559,858 | 8 qtrs |
| BlackRock Inc | Added | 17,723,537 | +5,350,664 | < 0.01% | $207,010,912 | 8 qtrs |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 14,842,976 | -353,579 | 0.03% | $173,365,959 | 3 qtrs |
| Patient Square Capital LP | Unchanged | 12,639,920 | 0 | 81.13% | $147,634,266 | 4 qtrs |
| BAKER BROS ADVISORS LP | Added | 11,877,171 | +2,448,579 | 0.8% | $138,725,357 | 4 qtrs |
| T Rowe Price Investment Management Inc | New | 10,649,397 | +10,649,397 | 0.09% | $124,385,000 | 1 qtr |
Filing details and methodology As reported
- Report period
- September 30, 2023
- Filed
- November 13, 2023
- Filing type
- 13F-HR
- Position type
- SHS
Voting authority reported
- Sole
- 5,872
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.